Agilent Technologies Inc Overview
Industry: Diagnostics & Research
Sector: Healthcare
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California. Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromat Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Agilent Technologies Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $1.8B (reported); EPS was $1.49 (reported).
Revenue
$1.8B
reported
EPS
$1.49
reported
Net income/share
$1.2
reported
Operating income
$399M
+21.7% YoY
What changed
- Revenue reported to $1.8B; EPS reported to $1.49.
- Operating income +21.7% YoY to $399M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
Jun 01, 2026
SEC filing
8-K
May 27, 2026
SEC filing
10-Q
Mar 03, 2026
SEC filing
8-K
Feb 25, 2026
Earnings release
Earnings release
Feb 25, 2026
SEC filing
10-K
Dec 22, 2025
SEC filing
8-K
Nov 24, 2025
Earnings release
Earnings release
Nov 24, 2025
SEC filing
10-Q
Aug 29, 2025
SEC filing
8-K
Aug 27, 2025
Earnings release
Earnings release
Aug 27, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Is Agilent Technologies (A) Undervalued Following Its FDA Approval For OPDIVO Companion Diagnostics?
Headline from Yahoo Finance UK: Is Agilent Technologies (A) Undervalued Following Its FDA Approval For OPDIVO Companion Diagnostics?
Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
Headline from Business Wire: Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma.
Agilent receives FDA approval for cancer diagnostic test
Headline from Investing.com UK: Agilent receives FDA approval for cancer diagnostic test.
Why Agilent Technologies (A) Is Up 5.4% After New FDA Nod For OPDIVO Cancer Test
Headline from Yahoo Finance: Why Agilent Technologies (A) Is Up 5.4% After New FDA Nod For OPDIVO Cancer Test.
Agilent stock rises on EU approval for cancer diagnostic By Investing.com
Headline from Investing.com South Africa: Agilent stock rises on EU approval for cancer diagnostic By Investing.com.
Agilent stock rises on EU approval for cancer diagnostic By Investing.com
Headline from Investing.com Australia: Agilent stock rises on EU approval for cancer diagnostic By Investing.com.
Earnings Per Share
Score 4.00/5
Agilent Technologies Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Thermo Fisher Scientific Inc
In
Diagnostics & Research industry
, IQVIA Holdings Inc
, Thermo Fisher Scientific Inc
, Medpace Holdings Inc
are companies with high ratings.
Return on Equity
Score 4.56/5
Agilent Technologies Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Thermo Fisher Scientific Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 4.84/5
Agilent Technologies Inc
commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include
Zoetis Inc
IQVIA Holdings Inc
Thermo Fisher Scientific Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 1.97/5
Agilent Technologies Inc
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Thermo Fisher Scientific Inc
have achieved high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios